Clinical Trials Logo

Actinic Keratosis clinical trials

View clinical trials related to Actinic Keratosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03024060 Withdrawn - Actinic Keratosis Clinical Trials

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

Start date: March 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to prove the safety and efficacy of Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution 20% followed by 10 J/cm2 of blue light delivered at 10 mW/cm2 or 20 mW/cm2 in the treatment of multiple actinic keratosis on the face or balding scalp (the Treatment Area), utilizing a 14-18 hour incubation period.

NCT ID: NCT02867722 Withdrawn - Actinic Keratosis Clinical Trials

Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States

DaylightPDT
Start date: December 2020
Phase: N/A
Study type: Interventional

In this study, daylight PDT will be administered to interested patients at Dana-Farber/Brigham and Women's Cancer Center. Daylight PDT has been shown to be an effective and painless alternative to traditional PDT. Daylight PDT involves application of the photosensitizer in the physician's office followed by exposure to daylight.

NCT ID: NCT01735942 Withdrawn - Actinic Keratosis Clinical Trials

Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions

Start date: October 2012
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to find out the effectiveness of ingenol mebutate compared to cryotherapy (freezing of the tissue) for the treatment of face and scalp skin lesions.

NCT ID: NCT00814528 Withdrawn - Actinic Keratosis Clinical Trials

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

Start date: November 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the treatment of skin growths called actinic keratoses (AK) with 5-ALA PDT, an FDA-approved treatment, versus treatment with other conventionally used FDA-approved agents such as cryotherapy, Imiquimod, or 5-fluorouracil (5-FU).